(IBBQ) Nasdaq Biotechnology - Overview
Etf: Biotechnology, Pharmaceuticals, Nasdaq
Dividends
| Dividend Yield | 1.03% |
| Yield on Cost 5y | 1.05% |
| Yield CAGR 5y | 14.68% |
| Payout Consistency | 100.0% |
| Payout Ratio | - |
| Risk 5d forecast | |
|---|---|
| Volatility | 18.8% |
| Relative Tail Risk | 2.62% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.14 |
| Alpha | 18.84 |
| Character TTM | |
|---|---|
| Beta | 0.682 |
| Beta Downside | 0.560 |
| Drawdowns 3y | |
|---|---|
| Max DD | 23.66% |
| CAGR/Max DD | 0.51 |
Description: IBBQ Nasdaq Biotechnology January 06, 2026
The Invesco Nasdaq Biotechnology ETF (NASDAQ: IBBQ) is a U.S.-based health-sector ETF that commits at least 90 % of its assets to the Nasdaq Biotechnology Index, a modified market-cap weighted basket of biotech and pharmaceutical stocks across large, mid, and small caps. Because the fund is classified as non-diversified, it may hold fewer than 40 securities, concentrating exposure to the sector’s most liquid constituents.
Key metrics to watch include the index’s average forward-price-to-earnings (forward-P/E) ratio, which typically hovers around 30–35 ×, reflecting high growth expectations, and the sector’s R&D intensity-average R&D spend as a share of revenue exceeds 20 % for many constituents. A primary driver of performance is the pipeline success rate: FDA approvals and Phase III trial outcomes can swing the ETF’s returns sharply, while macro-level factors such as biotech-focused venture capital fundraising and health-care policy (e.g., drug pricing reforms) set the broader backdrop.
For a deeper, data-rich analysis of IBBQ’s risk-adjusted performance and its exposure to emerging therapeutic areas, you might explore the ValueRay platform.
What is the price of IBBQ shares?
Over the past week, the price has changed by -0.88%, over one month by +3.68%, over three months by +11.88% and over the past year by +32.59%.
Is IBBQ a buy, sell or hold?
What are the forecasts/targets for the IBBQ price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 32.1 | 9.2% |
IBBQ Fundamental Data Overview February 02, 2026
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 72.9m USD (72.9m + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 72.9m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 72.9m / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 8.43% (E(72.9m)/V(72.9m) * Re(8.43%) + (debt-free company))
Discount Rate = 8.43% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)